Oscar Health, Inc. (OSCR) shares soared 5.29% in pre-market trading on Tuesday, despite reporting disappointing second-quarter results for 2025. The health insurance technology company's stock rally appears to be driven by its revised and potentially optimistic outlook for the full year 2025.
According to the company's preliminary financial results, Oscar Health reported a Q2 adjusted EBITDA of -$120 million, falling short of the IBES estimate of $116.9 million. The net income for the quarter stood at a substantial loss of $228 million. Despite these underwhelming figures, investors seem to be focusing on the company's forward-looking projections.
Oscar Health revised its 2025 guidance, now anticipating annual revenue between $12.0 billion and $12.2 billion. Additionally, the company expects a Medical Loss Ratio of 86.0% to 87.0% for 2025. These projections appear to have instilled confidence in investors, potentially indicating improved operational efficiency and growth prospects for the company. The market's positive reaction suggests that these forward-looking metrics may have exceeded previous expectations, overshadowing the current quarter's weak performance.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。